Activist investor David Lazar to invest $3M in LQR House

LQR House (NASDAQ:LQR) said on Wednesday that it has entered into a securities purchase agreement with activist investor David Lazar. Under the agreement, Lazar has committed to providing $3M in funding to LQR House.

Read More
2 min read

David E. Lazar Announces Ownership Interest in Minim, Inc.

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- David E. Lazar, an experienced private investor, today filed a Schedule 13D announcing his acquisition of 2,000,000 shares of Series A Convertible Preferred Stock ("Series A Preferred Stock") of Minim, Inc. ("Minim" or the "Company"). Each share of Series A Preferred Stock is convertible into 1.4 shares of the Company's common stock ("Common Stock").

Read More
1 min read

Titan Pharmaceuticals Shares Double on Reverse Merger Deal

Titan Pharmaceuticals shares rallied after the company entered into an agreement to combine with KE Sdn. Bhd. in a reverse merger .Shares in premarket trading on Tuesday more than doubled to $10.38.

Read More
1 min read

Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”).

Read More
4 min read

Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.

NEW YORK, June 10, 2022 (GLOBE NEWSWIRE) -- David E. Lazar, Chief Executive Officer of Activist Investing LLC (together with its affiliates, “Activist Investing” or “we”), one of the largest stockholders of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“TTNP” or the “Company”) with 9.9% of the Company’s outstanding shares, today issued the following statement:

Read More
1 min read

Lionel Messi’s fashion royalties and shipping’s road to Nasdaq

Heidmar is latest shipping company to opt for non-SPAC reverse merger. Some shipping listings are acquired from public companies that have nothing to do with shipping — which makes for some colourful Nasdaq origin stories.

Read More
4 min read

OpGen Announces Acquisition of Preferred Stock by David Lazar

ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”) of the Company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million.

Read More
3 min read

No Product, No Sales, No Prospects? Consider a Reverse Merger

Source: bloomberg.com/news, When all else has failed and a publicly traded company has no product and no prospects, it still has one thing that is worth a pot of gold — its listing.

Read More
2 min read

Minim Rises After Investor David Lazar Buys 2M Preferred Shares

Shares of Minim rose after investor David E. Lazar agreed to buy 2 million preferred shares of the provider of WiFi security software.

Read More
1 min read

Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock

SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreement (the “Purchase Agreement”) with The Sire Group Ltd. (“Sire Group”) for the sale of the Company’s newly designated Series AA Convertible Preferred Stock (the “Preferred Stock”).

Read More
2 min read

Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

SAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the “Agreement”) with Fedson, Inc., a Delaware Corporation (“Fedson”), for the sale of certain ProNeura assets including Titan’s portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology.

Read More
2 min read

Life Sciences Reverse Mergers Go Global: Is it the Path for Your Company?

Source: cooley.com, With the US initial public offering markets continuing to remain largely closed, and special purpose acquisition company combinations being costly and complex, there’s a new kid in town for foreign companies looking to go public in the US: reverse mergers.

Read More
4 min read